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Abstract
This article reviews recent advances in surgical 
techniques and adjuvant therapies for colorectal 
cancer, i nc lud ing to ta l mesorec ta l exc i s i on , 
the resection of l iver and lung metastasis and 
advances in chemoradiation and foreshadows some 
interventions that may lie just beyond the frontier. In 
particular, little is known about the intracellular and 
extracellular cascades that may influence colorectal 
cancer cell adhesion and metastasis. Although the 
phosphorylation of focal adhesion kinases and focal 
adhesion associated proteins in response to integrin-
mediated cell matrix binding (”outside in integrin 
signaling”) is well described, the stimulation of cell 
adhesion by intracellular signals activated by pressure 
prior to adhesion represents a different signal 
paradigm. However, several studies have suggested 
that increased pressure and shear stress activate 
cancer cell adhesion. Further studies of the pathways 
that regulate integrin-driven cancer cell adhesion may 
identify ways to disrupt these signals or block integrin-
mediated adhesion so that adhesion and eventual 
metastasis can be prevented in the future. 
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION
Colorectal cancer is a common cause of  morbidity and 
mortality. Although the basic principles of  screening, 
surgical resection when possible, and adjuvant therapy 
when indicated remain val id , considerable new 
information offers the possibility of  substantially 
improving outcomes for such patients in the future. This 
review will briefly summarize current epidemiologic and 
prognostic information about this disease for context, 
and then will focus on new approaches to surgery, 
adjuvant therapy, the management of  established 
metastasis, and the prevention of  metastasis. Although 
screening for colorectal neoplasm is crit ical for 
prevention, early diagnosis, downstaging, and improved 
survival, this subject has been extensively reviewed 
elsewhere[1-4] and is beyond the scope of  the current 
review.
INCIDENCE AND PREVALENCE
Colorectal cancer is the third most common cancer and 
the third leading cause of  cancer related mortality in the 
United States[5]. Colorectal cancer is also very common 
in Western Europe, Australia and New Zealand, whereas 
the age standardized incidence rate of  colorectal 
carcinoma is very low in India and Africa[6,7]. There 
seems to be an association of  higher incidence rates 
in colorectal cancer with increasing affluence[8]. Over 
the past decade, colorectal cancer rates have modestly 
decreased or remained level. Until age 50, men and 
women have similar incidence and mortality rates; after 
age 50, men are more vulnerable[5]. Colorectal cancer is 
generally a malignancy associated with the elderly, with a 
mean age at diagnosis of  73 years[9]. In the Netherlands, 
statistics showed that a peak incidence of  colorectal 
cancer for both men and women occur between the age 
of  70-79 years[10]. Before the age of  75 years, men and 
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women in the Netherlands have a 4.67% and 3.34% 
cumulative incidence to develop colorectal cancer[11]. 
By the age of  70 years, at least 50% of  the western 
population will develop some form of  colorectal tumor, 
spanning the spectrum from an early benign polyp to an 
invasive adenocarcinoma.
STAGE OF COLORECTAL DISEASE
The stage of  disease is one of  the most important 
prognostic factors for survival in patients with colorectal 
cancer. It is therefore clinically significant to know the 
relative incidence for each stage of  the disease. The 
incidence of  Stage Ⅰ disease in the United States has 
increased over the past years due to better screening 
and is currently around 30%. This is an important 
development since the detection of  early stage disease 
increases the chance for R0 resection and potential cure 
for colorectal cancer. The incidence of  Stage Ⅱ and Ⅲ 
disease are respectively 27% and 24%, while Stage Ⅳ 
disease is present in 19% of  patients in the United 
States. A remarkable observation is that older patients 
are diagnosed more frequently at an early stage (Stage 
0 and 1) and diagnosed three times less frequently with 
stage Ⅳ disease than younger patients. A possibility 
is that younger patients feel less at risk and ignore 
symptoms for a longer period of  time and are therefore 
diagnosed at a later stage[12].
The relative 5-year survival rates in the United 
States show that when the disease is detected early, at 
a localized stage, survival rates for Stage Ⅰ colon and 
rectal cancer are 93% and 92%, respectively. At Stage Ⅱ 
disease the 5-year survival rates are between 72%-85% 
for colon cancer and between 56%-73% for rectal cancer. 
The fluctuations in Stage Ⅱ survival rates are due to the 
fact that Stage Ⅱ disease includes both T3 (Stage ⅡA) 
and T4 (Stage ⅡB) tumors. For more advanced disease 
at diagnosis, the survival rates drop significantly. At 
Stage Ⅲ, the 5-year survival rates for colon and rectal 
cancer vary from 44%-83% and 30%-67% respectively. 
Again the wide range of  survival rates reflects the fact 
that Stage Ⅲ disease is further categorized into the 
following sub-categories, Stage ⅢA (T1-2, N1, M0), 
Stage ⅢB (T3-T4, N1, M0) and Stage ⅢC (any T, N2, 
M0) disease. For Stage IV colorectal disease the 5-year 
survival rate may be as low as 8%[13,14].
SURGICAL TREATMENT
Surgical management is the primary treatment of  
potentially curable colorectal cancer. In most cases, 
this involves resection of  the primary tumor and 
regional lymph nodes. However, treatment of  curable 
colorectal cancer patients may vary from endoscopic 
polypectomy for malignant polyps or local excision in 
carefully selected patients with limited rectal carcinomas 
to multimodality management for locally advanced 
rectal cancers or cancers invading adjacent organs. The 
objective in all cases is to maximize both oncologic 
and functional results. Due to the improvements in 
surgical techniques, as well as better screening and 
new developments in adjuvant therapy, the ratio of  
people with potentially curable disease has increased 
over the past decades. This evolution has included 
the development of  total mesorectal excision, the 
introduction of  laparoscopic surgery, the sentinel lymph 
node technique, curative resections of  liver and lung 
metastasis and improvements in adjuvant therapies such 
as chemotherapy and radiotherapy.
En bloc resection and the no-touch technique were 
first described in 1967 by Trumbell et al and remain 
valid and important[15]. The best prevention strategy 
of  potential tumor cell distribution is maintained by 
the surgeon strictly using the principles of  en-bloc 
resection. As the likelihood of  lymph node involvement 
increases with depth of  tumor invasion (5.6% for pT1, 
10% for pT2, 36.7% for pT3, and 77.7% for pT4 colon 
carcinoma)[16], invasive adenocarcinomas require ligation 
and resection of  the lymphovascular pedicle directly 
draining the intestinal segment containing the tumor. 
When the lesion is equidistant between two pedicles, 
then both should be encompassed in the resection. 
Another surgical option is the no-touch isolation 
technique with primary ligation of  the corresponding 
vessels, and dissection of  the lymph nodes[17-20]. The 
concept of  this technique is to avoid tumor manipulation 
during surgery so that shedding of  tumor cells into the 
lymphatic or vascular circulation is kept to a minimum. 
The presence of  free cancer cells within the lymphatic, 
vascular circulation or in the peritoneal cavity can be 
detected by mRNA coding using qPCR and is associated 
with a poorer prognosis for patients undergoing curative 
colorectal cancer surgery[21,22]. However, there seems to 
be limited benefit in the no-touch isolation group; the 
morbidity and mortality rates after a 5-year follow-up of  
patients were equal[20]. More recently, a study by Hayashi 
et al has suggested that the no-touch isolation technique 
may be useful to prevent cancer cells from being shed 
into the portal vein during surgical manipulation[23]. 
Today, en-bloc resection without the primary ligation 
of  corresponding vessels is still the more common 
technique.
Other advances in surgical techniques have resulted 
in less tumor recurrence and given patients with 
advanced colorectal disease the opportunity to undergo 
surgery with curative intent. In 1982 Heald developed 
an important surgical technique for the treatment of  
rectal cancer. The concept of  total mesorectal excision 
(TME) was introduced in conjunction with low anterior 
resection (LAR) as a means of  procuring all perirectal 
fat while facilitating sphincter preservation[24]. Recent 
studies have reported local recurrence rates of  around 
10% in various TME series[25-30]. In the study by Moore 
et al , local recurrence rates of  less than 5% have 
been reported with a distal margin of  1 cm, provided 
that the mesorectum can be excised as a complete 
lymphovascular package[31]. Today TME has been 
successfully taught as a standardized procedure and 
translated to other colorectal surgical environments with 
reproducible cancer-specific outcomes[32].
Advances in laparoscopic equipment and technique 
have revolutionized the surgical approach to many 
diseases. Laparoscopic surgery for colorectal cancer is 
currently considered an acceptable alternative to open 
resection for colorectal cancer. There are small but 
measurable short term benefits such as decreased post-
operative narcotic use, earlier return of  bowel function, 
shorter length of  stay and better cosmetic results. 
Today there is no question that laparoscopic surgery 
can be performed safely and effectively by experienced 
surgeons. There is enough evidence that survival rates 
are not compromised by the laparoscopic approach[33,34].
Although the first laparoscopic colon resection 
was reported in 1991[35], the adoption of  minimally 
invasive colon resection has been impeded by several 
factors. First, laparoscopic colon surgery is technically 
demanding. Second, and more importantly, there has 
been historical concern about whether minimally invasive 
surgery for colonic malignancies would achieve adequate 
oncologic resection. The most recent studies, including 
retrospective and prospective registries, as well as 
comparative studies clearly demonstrate that oncologic 
principles are not compromised by laparoscopic 
techniques, and the yield of  lymph nodes, surgical 
margins (proximal, distal and radial), and length of  bowel 
resected were comparable to open cancer surgery[17,36,37]. 
Another problem that has been discussed controversially 
is the issue of  whether laparoscopic surgery is associated 
with an increased hematogenous and intraperitoneal 
tumor cell distribution. Some studies have shown that 
there is a higher incidence of  intraperitoneal tumor 
cell dissemination during laparoscopic resection for 
colorectal cancer when compared to open surgery for 
colorectal cancer[38,39]. On the other hand, other studies 
have contradicted this observation[40,41]. Finally, another 
concern has been the incidence of  port-site metastasis 
after laparoscopic resection[16,42-45]. Although port-site 
metastases have not been restricted to laparoscopic 
surgery for colorectal cancer, the major impact of  
this phenomenon has been in this field. A closer 
look at the literature reveals most reports with a high 
incidence rate were small series published in the early 
1990s[44,45]. Within the last ten years, three large trials of  
laparoscopic surgery for colorectal cancer have been 
published that clearly demonstrated a low incidence of  
wound recurrence not statistically significantly increased 
compared to wound recurrence after open laparotomy 
sites[33,34,46]. However, it should be cautioned that these 
trials were not adequately powered to fully address 
the question. Moreover, in the COST-trial[33], wound 
recurrence rates demonstrated an incidence of  port site 
recurrence that, although both low and not statistically 
significantly different from that after open surgery, 
was nevertheless more than twice the rate of  wound 
implantation seen after open surgery (0.5% incidence in 
the laparoscopic arm vs 0.2% in the open surgical arm of  
the trial). Although the question therefore still has not 
been completely addressed, it appears that the incidence 
is quite low and within acceptable clinical range, and 
it seems dubious that a randomized trial of  sufficient 
size ever will be conducted to settle conclusively this 
issue. It seems likely that insufficient technical skills 
and experience at the beginning of  the laparoscopic 
era contributed to the early reports that described 
considerably higher rates of  port site recurrence.
Many cancers, including colorectal cancer, spread 
first to the lymph nodes before reaching other parts 
of  the body. Lymph node status remains one of  the 
most important prognostic factors in the management 
of  colorectal cancer. In patients without nodal disease, 
recurrent tumors still develop in about 15% to 20% of  
cases within 5 years of  diagnosis[47]. The reasons for this 
are unclear, but may depend upon the quality of  surgical 
resection and conventional pathologic review. Node-
negative patients are usually not treated with adjuvant 
chemotherapy outside a clinical trial because of  the lack 
of  definitive evidence of  survival benefit. Patients with 
nodal disease, on the other hand, should be treated with 
adjuvant chemotherapy because of  potential reduction 
of  mortality up to 33%[48]. Therefore, it is critical to 
avoid pathological understaging of  the specimen. 
Standard pathologic evaluation may overlook low 
volume nodal metastasis, thereby failing to identify nodes 
imperative to accurate staging. Inconsistencies in number 
of  nodes harvested at time of  pathologic processing 
impact significantly colon cancer staging accuracy. This 
nodal sampling error serves as the basis for guidelines 
establishing a 12 node minimum for adequate staging 
utilizing conventional techniques [49]. Up to 78% of  
metastases are identified in subcentimeter nodes that 
may be overlooked during standard gross pathologic 
dissection of  resected specimens[49-51]. Microscopic 
examination of  1 or 2 hematoxylin and eosin-stained 
sections of  a 5-mm node limits pathologic assessment to 
< 1% of  the entire node, making identification of  small 
tumor cell aggregates challenging. In a study by Saha 
et al, sentinel lymph node mapping appears superior to 
conventional pathologic review and may therefore be a 
useful method to avoid understaging[47]. Nodal positivity 
was 48% for the group assigned sentinel-lymph-node 
mapping, compared with 35% for the group assigned 
conventional staging (P < 0·001). In this study, sentinel 
lymphatic mapping accounts for the upstaging of  13% 
of  colon cancer. In other studies, sentinel lymph node 
mapping accounts for the upstaging of  19%-24% of  
patients[52-57]. The consequence of  upstaging is that 
these patients now become candidates for adjuvant 
chemotherapy. After a minimum of  2 years follow-
up, patients assigned nodal mapping (n = 153) had an 
overall recurrence of  7%, compared with 25% (n = 
162) for the patients assigned conventional staging (P 
= 0.001)[47,58]. As the sentinel lymph node technique has 
developed, some investigators describe over 90% success 
in identifying the sentinel node and accuracy rates of  
approximately 90%[47,53-56].
In patients with colorectal metastases, advances in 
surgical techniques have made it possible that the goal 
of  surgery is no longer palliative but of  curative intent. 
Therefore, a complication such as wound recurrence 
may have grave clinical consequences for patients that 
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are operated on with curative intent. It thus becomes 
increasingly important that surgeons minimize tumor 
spill into the peritoneal cavity or into the lymphatic/
vascular systems during surgical procedures for colorectal 
cancer. If  not, tumors may recur and compromise a 
potentially curative resection.
The liver is the most common site for colorectal 
metastasis, since the venous outflow of  the gut first 
reaches the liver through the portal system before 
flowing back into the systemic circulation. Approximately 
one-third of  patients diagnosed with colorectal cancer 
will develop synchronous or metachronous metastases 
to the liver. The incidence of  synchronous metastasis 
has ranged from 23.0% to 46.8%[59-62] and the 5-year 
survival rate after hepatic resection has been reported to 
be 14% to 40% in studies with more than 100 or more 
patients[60,61]. Several studies have suggested that careful 
selection of  patients for hepatic resection of  colorectal 
metastases can result in favourable survival[63-65]. A recent 
study by Rees et al found 7 risk factors (Basingstoke 
Prediction Index) that were found to be independent 
predictors of  poor survival in a multivariate analysis[66]. 
The 7 risk factors were number of  hepatic metastases 
> 3, node positive primary, poorly differentiated 
primary, extrahepatic disease, tumor diameter ≥ 5 cm, 
carcinoembryonic antigen level > 60 ng/mL, and 
positive resection margin. The first 6 of  these criteria 
were used in a preoperative scoring system and the last 
6 in the postoperative setting. Patients with the worst 
postoperative prognostic criteria had an expected median 
cancer-specific survival of  0.7 years and a 5-year cancer-
specific survival of  2%. Conversely, patients with the 
best prognostic postoperative criteria had an expected 
median cancer-specific survival of  7.4 years and a 
5-year cancer-specific survival of  64%[66]. It is therefore 
very important to preoperatively assess if  resection is 
achievable, most preferably with a 1 cm margin[67,68]. It is 
often difficult to measure a 1 cm distance to the tumor 
edge on the specimen because of  dissection or cautery 
artifact. Other times a surgical margin of  1 cm cannot 
be obtained because of  the relation of  the tumor to the 
hepatic veins, portal veins, or vena cava. When tumor is 
left behind after surgery, meaning that RO resection is 
not achieved, the survival is not different than that in the 
nonresected group.
While surgical resection remains the gold standard of  
therapy, only a few patients are suitable candidates for 
curative surgical resection because of  the presence of  
liver malignancy in unresectable locations, the number 
of  and anatomic distribution of  tumor lesions, or the 
presence of  extrahepatic disease or poor liver function. 
An alternative treatment to control and potentially cure 
liver disease has been developed for use in patients with 
malignant liver tumors. Radiofrequency ablation (RFA), 
also known as “radiofrequency thermal ablation”, is a 
recently developed thermoablative technique. It induces 
temperature changes by using high-frequency alternating 
current applied via electrodes placed within the tissue 
to generate areas of  coagulative necrosis and tissue 
desiccation[69,70]. Overall recurrence for colorectal cancer 
was most common after RFA (84% vs 64% RFA and 
resection vs 52% resection only, P = 0.001)[71]. Thus, RFA 
has been reserved as an adjunctive tool to resection, 
when complete resection is not possible, either alone or 
in combination with resection[72-74]. The study by Abdalla 
et al demonstrates that RFA alone or in combination 
with resection for unresectable patients does not provide 
survival comparable to resection, and provides survival 
only slightly superior to nonsurgical treatment[71].
After colorectal metastases to the liver, the lungs 
are the second most common site of  metastasis. The 
number of  possibly resectable cases of  lung metastasis 
after primary surgery for colorectal cancer has increased 
considerably over the past 20 years. The typical pattern 
of  lung metastasis is single or multiple nodules rather 
than miliary tumors or lymphangitis carcinomatosa. 
No effective chemotherapy regimen has been found 
for metastatic disease. Hence, a surgical procedure to 
eliminate pulmonary metastases is generally accepted 
as the only potentially curative treatment. In favor of  
surgery is the recent trend toward earlier detection of  
pulmonary metastases as small peripheral densities with 
increasingly common use of  screening with spiral or 
high-resolution computed tomography. The reported 
5-year survival rates for lung metastectomy surgery 
were 24% to 63%, and most were around 40%[75-90]. 
The criteria for resection of  pulmonary metastases 
from colorectal carcinoma included unilateral or 
bilateral excisable lung lesions per preoperative chest 
radiography, no local recurrence of  primary lesions, 
and no extrapulmonary lesions with the exception of  
associated prior or simultaneous resectable hepatic 
metastases. Elevated CEA level and the number of  
metastasis are the most significant prognostic factors for 
overall survival after resection of  lung metastases from 
colorectal cancer[91].
ADJUVANT THERAPY
For the treatment of  rectal cancer, adjuvant radiotherapy 
has become a standard procedure. The following two 
schedules of  treatment have been explored over the 
last decades: short term treatment that delivers 25 Gy 
in 5 fractions during 1 wk, followed immediately by 
surgery, and conventional schedules that deliver 40 Gy 
to 50 Gy in 20-25 fractions during 4 to 5 wk, followed 
by surgery 3-6 wk later. Regardless of  the schedule, 
preoperative radiotherapy decreases local recurrence 
rates by 50%-60% when compared to surgery alone[92,93]. 
The conventional schedules are delivered in combination 
with chemotherapy to patients with locally advanced 
rectum cancer (T3-T4 tumors and N+ disease). The 
radiobiological dose delivered in a short term treatment 
schedule is too low for adequate response in locally 
advanced rectal tumors. In 2001, a study by Marijnen 
et al demonstrated that short term treatment with 25 
Gy during 1 wk did not achieve tumor down staging 
for T1-T3 tumors within a period of  10 d[94]. However, 
a schedule of  50.4 Gy given over a period of  6 wk 
in combination with 5-FU and leucovorin did cause 
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down staging of  locally advanced rectum tumors[95]. 
Today the standard treatment for locally advanced 
rectum carcinoma is pre-operative radiotherapy in 
combination with 5-FU and leucovorin[96]. In addition, 
it has been demonstrated that timing of  chemoradiation 
for locally advanced tumors is important, since less 
toxicity and better local control may be achieved when 
chemoradiation is given pre-operatively instead of  post-
operatively[97]. Thus far, there has been no conclusive 
demonstration of  a gain in overall survival for patients 
with locally advanced rectal tumors treated with adjuvant 
chemoradiation[98].
During the past years, various phase Ⅰ and Ⅱ 
trials have been performed with capecitabine[98,99]. It 
is a form of  chemotherapy that is administered orally 
and is a tumor activated fluoropyrimidine carbonate. 
During the last of  three enzymatic processes, thymidine 
phosphorylase converts capecitabine to 5-FU. The 
enzyme thymidine phosphorylase is found in high 
concentrations in rectal tumors and it is therefore less 
likely that healthy tissue within the radiation field is 
subjected to 5-FU. The advantages of  this form of  
therapy are less toxicity, oral administration, and less 
chance of  infections since a venous port access catheter 
is no longer necessary. Although the phase Ⅱ trials with 
capecitabine in combination with radiotherapy for locally 
advanced rectum tumors show promising results, there 
are currently no phase Ⅲ trials that give information 
about local recurrence during a long term follow-
up period. However, the National Surgical Breast and 
Bowel Project trail in the United States is planning on 
performing such a study in the near future. If  the results 
from this study show acceptable local recurrence rates, 
then capecitabine may replace the 5-FU/leucovorin 
schedule. A study by Kim et al suggests that the 
addition of  leucovorin to capecitabine does not work 
synergetically but actually seems more toxic[100]. For this 
reason a combined capecitabine and leucovorin schedule 
does not seem desirable. Other phase Ⅰ and Ⅱ studies 
have tried to combine capecitabine with oxaliplatin[101-103]. 
The results seem promising as well, and grade Ⅲ/Ⅳ 
toxicity does not seem greater than the capecitabine and 
5-FU/leucovorin schedules. Although there are many 
new developments, 5-FU and leucovorin in combination 
with radiotherapy remains the standard of  neo-adjuvant 
treatment in most countries for patients with locally 
advanced rectum carcinoma.
Although research efforts continue to be directed 
at deriving new cytotoxic and antiproliferative agents 
directed specifically at cancer cells, the concept of  
targeting the angiogenic support of  tumors has recently 
become of  interest, and angiogenesis inhibitors have also 
been introduced for treatment of  cancer. Bevacizumab 
is an anti-VEGF antibody. When combined with 
conventional chemotherapy, this agent has been reported 
to prolong survival in patients with advanced colorectal 
cancer treated in a palliative setting[104,105]. Additionally, 
recent trials with neo-adjuvant chemotherapy suggest 
that irresectable liver metastases can be downstaged 
with this agent. Thus, an increasing number of  patients 
with colorectal metastases to the l iver may now 
become candidates for liver resection. Indeed, in such 
patients preoperative treatment with bevacizumab and 
chemotherapy may be associated with less blood loss 
compared to chemotherapy alone[106]. If  bevacizumab 
and chemotherapy are discontinued at least 8 wk before 
hepatic resection, the addition of  bevacizumab to 
preoperative irinotecan and oxaliplatin does not increase 
morbidity after hepatic resection[106,107]. Unfortunately, 
there are no studies yet that compare whether the 
combination of  bevacuzimab and chemotherapy 
allows for better downstaging of  liver metastases than 
conventional chemotherapy alone. This will be an 
important subject for future study, as will the long term 
outcomes of  patients downstaged with these agents 
and then subjected to liver resection of  the remaining 
obvious metastases.
Despite all of  these advances in surgical techniques 
and adjuvant therapies, colorectal tumor recurrence 
remains a problem. Manfredi et al described a 5-year 
cumulative rate of  local recurrence of  12.8% and a 
25.6% per cent rate of  distant metastases[108]. During 
surgery it is important that tumor free margins of  the 
resected specimen are achieved and that tumor spill 
is avoided. Unfortunately, some tumor spill occurs 
in approximately half  of  patients that are operated 
for colorectal cancer[109]. Many research studies have 
provided evidence for direct implantation of  the 
port site or surgical wound by exfoliated cancer cells, 
hematogenous seeding, tissue manipulation, serolization 
by pneumoperitoneum, patient’s positioning and 
immune dysfunction as potentially etiologic factors. 
Approximately 0.2%-1% of  patients will eventually 
develop wound recurrence[33,110]. Many of  these patients 
also exhibit more diffuse peritoneal recurrence, although 
approximately half  exhibit isolated wound recurrence. 
Either phenomenon has a negative impact on survival 
for those patients that are operated with curative intent. 
Since more than 80% of  patients with colorectal disease 
are initially operated with curative intent, a complication 
such as wound or peritoneal recurrence may drastically 
influence their 5-year survival rate in a negative manner.
TUMOR CELL ADHESION
The contrast between the high rates of  tumor cell 
spillage and circulating tumor cells and the much lower 
rates of  clinical tumor metastasis or implantation 
after surgery suggests that tumor implantation may be 
regulated in some way. The mechanisms that determine 
which tumor cells adhere to target organs and tissues are 
poorly understood. Normally, if  a cell is unable to attach 
to the extracellular matrix, it dies through induction of  
the cell suicide program known as apoptosis. Cancer 
cells, however, develop a means to avoid death in this 
situation. Cells that have suffered irreparable DNA 
damage activate specific proteases and nucleases that 
destroy the proteins and DNA of  the cell, thereby 
effectively limiting the spread of  potentially deleterious 
mutations. Cancer cells often exhibit mutations in genes 
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involved in regulating this pathway.
Since not all cancer cells that are shed into the 
peritoneal cavity undergo apoptosis, there is always a 
possibility that these cells will eventually cause wound 
metastasis. Tumor implantation begins with the adhesion 
of  tumor cells to the matrix proteins in the wound. 
The extracellular matrix consists chiefly of  type Ⅰ and 
Ⅳ collagens, laminins, heparin sulfate proteoglycan, 
fibronectin, and other noncollagenous glycoproteins[111]. 
Cell adhesion to extracellular matrix proteins is mediated 
by diverse receptors, most notably by members of  the 
integrin family. Integrins, heterodimeric transmembrane 
proteins, are composed of  noncovalently associated 
alpha and beta subunits that define the integrin-ligand 
specificity[112], and their pattern of  expression is likely to 
promote specific cellular adhesions. Both the physiologic 
status of  the cell[113] and divalent extracellular divalent 
cation concentrations[114] can influence the affinity 
between integrins and their ligands. After adhesion of  
the cell, proliferation and angiogenesis are then required 
to support tumor growth, invasion and subsequent 
metastasis.
Treatments to prevent wound or peritoneal metastasis
During the past years not much progress has been 
booked in reducing wound recurrence in patients with 
curable colorectal cancer. The application of  topical 
ointments[115,116], abdominal irrigation[117] and port-
site resection of  wounds[118] have had limited success. 
The most promising results to date are probably the 
studies that investigate the anticancer effect of  COX-2 
inhibitors. Various studies have shown that COX-2 
inhibitors have both antiangiogenic[119,120] and apoptotic 
effects[121,122] on human colon cancer cells. A more 
recent study demonstrated that COX-2 inhibitors down-
regulated β1-integrin expression, with consequent 
impairment of  the ability of  colon cancer cells to adhere 
to and migrate on extracellular matrix in an in vitro 
study[115]. It is therefore possible that these drugs may 
reduce wound recurrence since they may interfere with 
the adhesion of  the cell to extracellular matrix. However, 
to date, the mechanisms of  drug action and interaction 
are still far from clear, and their roles within the clinical 
setting are yet to be observed. It is therefore important 
to further investigate factors that may be of  significance 
during wound implantation and eventual tumor 
formation.
Extracellular influences on colon cancer cell adhesion
Interaction between cells and the extracellular matrix 
are in large part mediated by integrins in divalent cation-
dependent processes. This means that extracellular 
processes that alter divalent cation concentrations 
may also influence colon cancer cell adhesion to the 
extracellular matrix. Local shifts in the concentrations 
of  extracellular Mg2+ and Ca2+ occur during wound 
healing, impacting the function of  divalent cation-
dependent cell surface molecules responsible for cell-
cell and cell-extracellular matrix interactions[123]. Early 
in the process, when cell migration into the wound is 
initiated, Mg2+ is elevated and Ca2+ is reduced. As wound 
healing progresses, wound concentrations of  Mg2+ and 
Ca2+ return to normal plasma levels. Ebert et al reported 
that Mn2+ and Mg2+ stimulate binding of  HT-29 colon 
cancer cells to extracellular matrix proteins[124], and 
similar effects have been described in SW 620 and 
Caco-2 human colon cancer cells[125]. However, calcium 
inhibits adhesion of  SW 620 and Caco-2 human colon 
cancer cells to collagen Ⅰ, which is the dominant 
collagen of  the interstitial matrix[125]. Furthermore, Mg2+ 
and Mg2+ potentiate cancer cell adhesion to murine 
surgical wounds and subsequent tumor development. 
In contrast, Ca2+ inhibits cancer cell adhesion to 
murine surgica l wounds and subsequent tumor 
development[126]. The biological and chemotherapeutic 
response characterization of  transplantable mouse colon 
tumors suggests that they are reasonable models for 
colon cancer in humans[127]. Although more studies are 
required, these results raise the possibility that in the 
future, manipulation of  divalent cation concentrations in 
irrigation of  the surgical site may diminish perioperative 
tumor implantation.
Effects of physical forces on colon cancer cell adhesion
Cancer cells are subjected to pressure during surgical 
manipula t ion and passage through the venous 
and lymphatic system. Cells that are shed into the 
peritoneal cavity postoperatively are also subjected to 
increased pressure from postoperative edema. Surgical 
manipulation during either laparoscopic or open 
procedures is likely to result in the direct application 
of  much higher pressures to tumors or lymphatic 
channels containing malignant cells. For instance, 
during laparoscopic colectomy for cancer, intra-
abdominal pressure is often increased by 15 mmHg as 
the abdominal cavity is expanded to provide room to 
operate. The pressure engendered by a surgical forceps 
grasping tissue may be as high as 1500 mmHg[128]. 
Although pressure by the surgeon’s hand during tumor 
dissection has not been quantified to our knowledge, 
parallel studies suggest that intraocular pressures may 
exceed 50 mmHg during ocular manipulation during 
enucleation[129]. Normal portal venous pressures may be 
as high as 10 mmHg, and this may increase substantially 
in portal hypertension. Mesenteric venous pressures 
may exceed this under normal circumstances to generate 
portal flow and might be accentuated by intra-abdominal 
pressure generated by ascites, Valsalva maneuvers, 
or bowel edema after surgery. Mesenteric lymphatic 
pressures in the setting of  tumor infiltration into the 
lymphatics are unclear but might also be expected to 
be of  similar orders of  magnitude. Tumor cells in the 
systemic arterial circulation, of  course, are exposed to 
substantially higher pressures.
Physical forces such as shear stress, and pressure have 
been reported to affect colon cancer cells[130]. Increasing 
ambient pressure and the application of  shear stress 
increased cell adhesion of  several colon cancer cell lines 
and primary human colon cancer cells isolated directly 
from surgical specimens[130,131]. Indeed, an increase of  
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15 mmHg above ambient pressure had a maximum 
effect on colon cancer cell line adhesion in vitro[130]. An 
interesting observation is that during colorectal cancer 
surgery cells are shed into the abdominal cavity and 
subjected to increases in shear during irrigation and 
increased pressure during and after surgical procedures. 
Such increases in pressure may enhance the adhesion 
of  shed cells to surgical sites. Although these original 
studies were performed in vitro, 30 min exposure to 
15 mmHg increased pressure has more recently been 
demonstrated to increase cancer cell adhesion to murine 
surgical wounds[132] and to adversely affect survival in 
a murine transplantable tumor model[133]. There are 
obviously manifest differences between transplantable 
tumors in mice and the pathophysiology of  human colon 
cancers, but as these same signal events have also been 
described in primary human colon cancer cells[130,131], the 
animal data are suggestive that the same pathway might 
affect the development of  metastatic tumors in humans. 
The effect of pressure on focal adhesion-associated 
proteins
If  pressure and shear stimulate the adhesion of  cancer 
cells[125,130], it may then be important to unravel the 
intracellular mechanisms that mediate this effect so 
that interventions can ultimately be targeted to prevent 
cancer cell adhesion. In many cells, the focal adhesion 
kinase FAK transduces signals after adhesion through 
association with the cytoplasmic domains of  integrin 
subunits[134]. However, “inside-out signaling” by which 
intracellular events modulate integrin function is less 
well understood. A study by Cooke et al suggests 
that mechanical stimulation of  enterochromaffin-
derived BON cells directly or indirectly stimulates a G 
protein-coupled receptor that activates Gαq, mobilizes 
intracellular calcium, and causes 5-HT release[135]. 
Although this study did not portray increased adhesion 
due to mechanotransduction, it did show that shear 
stress on carcinoid cells activate an intracellular cascade 
that releases 5-HT. Consistent with such force-activated 
intracellular signaling, Thamilselvan et al demonstrated 
that extracellular pressure may increase integrin affinity 
and promote colon cancer adhesion in vitro via actin-
dependent inside-out FAK and Src signals[136]. Indeed, 
it is likely that the intracellular cascade involved in 
colon cancer cell adhesion to extracellular matrix is very 
complex. Recently, the activation of  PI 3-kinase/Akt 
signaling pathway has been correlated with prostatic 
metastasis[137], colon cancer cell invasion[138] and post-
operative growth[139]. The overexpression of  the PI 
3-kinase/Akt pathway has also been described in human 
cancers including ovarian and colonic carcinomas[140,141]. 
Recent studies suggest that the PI 3-kinase/Akt pathway 
may also be required for pressure-stimulated cancer cell 
adhesion[142], acting specifically via Akt-1[143].
Several key str uctural prote ins a lso seem to 
be involved in the mechanotransduction pathway, 
including cytoskeletal elements[144], the adapter proteins 
paxillin[145,146] and alpha actinin-1[147]. Both paxillin and 
alpha actinin-1 facilitate focal adhesion formation 
and physically link integrin-associated focal adhesion 
complexes with the cytoskeleton. These focal adhesion 
associated proteins are often abnormally expressed 
or mutated in cancer cells[148-150]. Therefore, they may 
be important in tumor biology in general. Although 
these focal adhesion associated proteins are not kinases 
themselves, these proteins facilitate the interaction of  
various kinases and other proteins required for this 
pathway to function. This makes them a promising 
target to uncouple the pathway required for force-
activated adhesion without actually inhibiting cellular 
kinases, possibly leading to fewer side effects. Indeed, 
in a preliminary proof  of  principle, knockout of  
alpha actinin-1 has been shown to abolish the effect 
of  pressure on tumor-free sur vival in a murine 
transplantable tumor model[133].
CONCLUSION
Over the past decades, screening for colorectal neoplasm 
has shown to be critical for prevention, early diagnosis, 
downstaging, and improved survival. Beyond intensified 
screening programs, surgical techniques have evolved 
over the past years. Total mesorectal excision has 
improved survival rates for rectal cancer[92]. Other major 
advances have included liver and lung resections for 
patients with colorectal metastasis, so that at least some 
of  these patients are no longer candidates for palliative 
treatment but instead can be treated with curative intent. 
Besides improvements in surgical techniques, adjuvant 
therapies such as radiotherapy and chemotherapy also 
have undergone improvement. At this moment, sentinel 
lymph node mapping is a technique that lies on the 
frontier, as does the proper role of  anti-angiogenesis 
agents. Some studies suggest that the sentinel lymph 
node technique may upstage a significant number of  
patients who then become candidates for chemotherapy, 
while anti-angiogenic therapy may downstage patients 
who then become candidates for surgical resection of  
known metastases. However, before conclusions are 
made on these points, further follow-up of  patient 
cohorts will be necessary. The cellular biochemistry 
involved in metastasis currently lies beyond the frontier. 
Unfortunately, little is known about the intracellular 
and extracellular cascades that may influence colorectal 
cancer cell adhesion and metastasis. Several studies 
have suggested that increased pressure and shear 
stress activate cancer cell adhesion. Further studies of  
the pathways that regulate integrin-driven cancer cell 
adhesion may identify ways to disrupt these signals or 
block integrin-mediated adhesion so that perioperative 
adhesion and eventual metastasis can be prevented in the 
future, adding yet another strategy to combat colorectal 
malignancy.
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